Trial to Test Safety of Adding Capivasertib to a Standard Leukemia Treatment Regimen
Phase 1/2
104
about 6 years
18+
1 site in IL
About this study
Researchers are testing the safety of adding capivasertib to a standard leukemia treatment regimen. The trial will test different doses of capivasertib in adults with leukemia and lymphoma, along with venetoclax and chemotherapy. It aims to find the safest dose of capivasertib for this combination therapy.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Blinatumomab
- 2.Take Capivasertib
- 3.Take Nelarabine
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
blinatumomab, capivasertib, nelarabine, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), venetoclax
injection, intravenous, oral (Oral Tablet), injection (Injection), infusion, oral
Secondary: Overall survival [Cohort 2 and 3], Progression free survival [All Cohorts], Rate of CR with measurable residual disease (MRD) negativity [Cohort 1], Rate of clinical remission (CR) [Cohort 1]
Oncology